Table 1.
Clinicopathological associations of moesin expression in patients with cervical cancer
| Moesin immunostaining | |||||
|---|---|---|---|---|---|
| Total number of cases | - | + | ++ | +++ | |
| Normal cervical tissues (NC) | 20 | 8 (40%) | 11 (55%) | 1 (5%) | 0 (0%) |
| cervical intraepithelial neoplasia (CIN) | 24 | 2 (8.3%) | 18 (75%) | 3 (12.5%) | 1 (4.2%) |
| Cervical squamous carcinoma | 42 | 4 (9.5%) | 13 (31%) | 15 (35.7%) | 10 (23.8%) |
| stage I (SC(I)) | 22 | 2 | 8 | 8 | 4 |
| stage II (SC(II)) | 20 | 2 | 5 | 7 | 6 |
| Lymph node metastasis | |||||
| With | 10 | 0 | 1 | 2 | 7 |
| Without | 32 | 4 | 12 | 13 | 3 |
NOTE: Interpretation of moesin staining was described in Materials and Methods. Moesin staining was graded as negative (-; score: 0-1), weak (+; 2-4), moderate (++; 5-8), and strong (++; 9-12).